Takeda Oncology Products. OSAKA, Japan & CAMBRIDGE, Mass. View results by evidence typ
OSAKA, Japan & CAMBRIDGE, Mass. View results by evidence type and category. Learn about approved medicines in the United States. Learn more. By embedding data, digital and technology across research and development, we will deliver our new medicines to patients faster. Sun Pharma will acquire Checkpoint Therapeutics and an FDA Takeda secures European Commission approval for FRUZAQLA (fruquintinib), a novel targeted therapy for previously treated Takeda (TSE:4502/NYSE:TAK) today announced financial results for fiscal year 2024 (period ended March 31, 2025) with continued strong momentum in Growth & Launch Takeda will showcase its oncology pipeline and product portfolio at the 2024 ASCO Annual Meeting. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, . Takeda Oncology (originally Millennium Pharmaceuticals) is a biopharmaceutical company based in Cambridge, Massachusetts. Takeda’s revamped R&D strategy means the drugmaker’s oncology leaders are prioritizing work in tumors across thoracic, Takeda (TSE: 4502/NYSE:TAK) today announced that it will present data from its expanding oncology pipeline and established product portfolio at the 59th Annual Meeting of - Innovative Oncology and Rare Disease Candidates: Takeda is broadening its oncology portfolio with several promising candidates slated for regulatory review in the near At Takeda, we are growing our oncology pipeline through a combination of internal innovation and strategic collaboration. Latest Takeda Oncology news: clinical trial results, FDA approvals, congress presentations & breakthrough cancer research. Gastroenterology Neuroscience Hematology & Rare Diseases Plasma-Derived Therapies Established Brands Oncology Home Oncology Hematology Immunology Browse All Products View All ACTOPLUS MET ACTOPLUSMET 15MG/500MG 60CT TRADE BTL (15 mg pioglitazone (as the base)/500 mg metformin Find information about medical research at Takeda, including our products, pipeline, and disease education created by our Oncology Medical Affairs team for healthcare professionals in the US. Our oncology R&D activities are focused on translating science into curative or transformative potential treatments by targeting tumor vulnerabilities and through novel strategies that Find information about medical research at Takeda, including our products, pipeline, and disease education created by our Oncology Medical Affairs team for healthcare professionals in the US. Tom Spalding is Head of Global Oncology Products and Pipeline Strategy for Takeda in the Oncology Business Unit, where he leads global marketing, new product planning, search and Gastroenterology Neuroscience Hematology & Rare Diseases Plasma-Derived Therapies Established Brands Oncology Takeda will showcase its oncology pipeline and product portfolio at the 2024 ASCO Annual Meeting. Takeda and Halozyme announce global collaboration and license agreement for use of drug delivery technology with vedolizumab. Our research and development efforts are focused on Takeda is sharpening its oncology focus amid an R&D revamp. We aim to discover and deliver life-transforming treatments in our core Takeda Oncology Pipeline Beginning with patients’ needs, we build our pipeline by identifying the most promising science and collaborate with leading teams around the globe to accelerate Takeda's pipeline is diverse and dynamic, with first-in-class molecules that address areas of high unmet need. We're committed to accelerating a Takeda Forward-Looking Statements This press release and any materials distributed in connection with this press release may contain forward-looking statements, Explore the Takeda-sponsored research articles and publications published on the products. Learn about Takeda Oncology products and pipeline for hematologic malignancies and solid tumors. Takeda Oncology is at the forefront of cancer research and development, bringing transformative medicines to patients worldwide. Takeda is a patient-focused, R&D-driven global biopharmaceutical company committed to bringing Better Health and a Brighter Future. Select your region for medicines by country. Takeda and Protagonist Therapeutics have jointly submitted a new drug application (NDA) seeking approval from the US Food and Drug Administration (FDA) for rusfertide to FDA-approved Takeda cancer therapies available in the US. Find prescribing information, safety data Search Takeda's approved cancer treatments worldwide. -- (BUSINESS WIRE)-- Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) Takeda Oncology (originally Millennium Pharmaceuticals) is a biopharmaceutical company based in Cambridge, Massachusetts. & NEWARK, Calif. Search the Medical Information Database to find information and resources about Takeda Oncology products, pipeline and disease states. Takeda Oncology Here2Assist is a comprehensive program committed to helping patients navigate insurance coverage requirements, identify available financial assistance and connect In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. About Takeda Takeda is focused on creating better health for people and a brighter future for the world. It is a fully owned subsidiary of Takeda Pharmaceutical.